Zoledronic acid in the management of malignant pleural mesothelioma
ISRCTN | ISRCTN45536692 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN45536692 |
EudraCT/CTIS number | 2015-004433-26 |
Secondary identifying numbers | 30497 |
- Submission date
- 27/07/2016
- Registration date
- 09/08/2016
- Last edited
- 21/04/2020
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English summary of protocol
Contact information
Scientific
Clinical Research Centre - Respiratory
Southmead Hospital
North Bristol NHS Trust
Bristol
BS10 5NB
United Kingdom
0000-0002-3884-1345 |
Scientific
Level 2, Learning and Research Building
Southmead Hospital
Bristol
BS10 5NB
United Kingdom
0000-0002-0060-9671 | |
Phone | +44 117 4148041 |
Duneesha.defonseka@nbt.nhs.uk |
Study information
Study design | Randomised; Interventional; Design type: Treatment, Drug, Imaging |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | A double-blind randomised controlled trial (RCT) to assess the feasibility of giving Zoledronic acid alongside chemotherapy in patients with mesothelioma to design a larger trial to assess the efficacy of Zoledronic acid alongside first line chemotherapy |
Study acronym | ZOL-A |
Study objectives | The aim of this study is to investigate the feasibility of running a trial to establish the role of zoledronic acid (ZA) in patients who have mesothelioma and are undergoing or eligible for chemotherapy. |
Ethics approval(s) | East of England - Cambridge East Research Ethics Committee, 10/05/2016, ref: 16/EE/0105 |
Health condition(s) or problem(s) studied | Specialty: Respiratory disorders, Primary sub-specialty: Respiratory disorders; UKCRC code/ Disease: Cancer/ Malignant neoplasms of respiratory and intrathoracic organs |
Intervention | Patients will be randomised using varying block sizes on a 1:1 to one of two groups using web based software developed by Sealed Envelope. Randomisation will be stratified according to histological subtype. Participants will be allocated to either the IMP (Zoledronic acid) or placebo arms. Participants in both arms of the trial will receive the infusion on the day of their chemotherapy, just prior to start of their chemotherapy treatment. They will have the same number of cycles of the IMP/placebo, as chemotherapy. Those who stop chemotherapy treatment early will stop IMP/placebo treatment too. A renally adjusted dose of Zoledronic acid or placebo will be administered in 100ml of 0.9% saline via an intravenous cannula over 15 minutes alongside each session of chemotherapy (every 3 weeks, up to a maximum of 6 cycles). Randomised patients will be stratified by histological subtype and allocated to either Zoledronic acid or placebo. A third non-randomised arm of the trial is available to patients who decline chemotherapy but would like an opportunity to have Zoledronic acid on its own (every 3 weeks, up to a maximum of 6 cycles). Follow up will occur after each cycle, at end of treatment and at 6 months, and involves information gathering on any AEs or SAEs relating to the IMP. Participants will also have blood tests at their follow-up appointments to ensure they are able to continue with the next cycle of chemotherapy treatment/IMP or placebo. |
Intervention type | Other |
Primary outcome measure | 1. Recruitment rate is recorded as the number of eligible participant who consent to participate in the study by 6 months 2. Acceptability of recruitment procedures, consent and randomisation, and data collection methods are measured through patient interviews conducted at 6 months 3. Tolerance of the IMP treatment will be measured by the proportion of patients who complete the full 6 cycles of treatment 4. Intolerance will be recorded for those who are unable to continue to with the IMP due to electrolyte disturbances or AEs relating to the IMP and come off treatment before completing 6 cycles 5. Efficacy data will be measured using CT scans, PET-CT scans and Mesothelin bloods tests. On CT a > 15% reduction in the modified RECIST score would be classed as a disease response. CT will be performed at post 3 cycles and at 6 months from enrolment |
Secondary outcome measures | No secondary outcome measures |
Overall study start date | 01/04/2016 |
Completion date | 24/07/2018 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | Planned Sample Size: 70; UK Sample Size: 70 |
Total final enrolment | 22 |
Key inclusion criteria | 1. Histologically confirmed diagnosis of MPM 2. WHO performance status 0-1 3. Eligible for first line chemotherapy treatment Measurable disease on CT as per modified RECIST criteria (tumour thickness > 5mm) 4. Ability to give informed consent 5. Aged 18 years and over |
Key exclusion criteria | 1. Not fit for chemotherapy due to performance status or other comorbidities Previous chemotherapy for MPM 2. IV bisphosphonates in the 3 months preceding randomisation 3. Significant renal disease (eGFR < 30ml/min in the last 4 weeks) 4. Hypocalcaemia (current hypocalcaemia on treatment, evidence of hypocalcaemia on most recent blood tests - should be within last 6 weeks) 5. Pregnancy or lactation Age 6. Age < 18 years 7. Known allergy to bisphosphonates or excipients of its preparation 8. Severe untreated dental caries 9. Concomitant participation in another drug trial for mesothelioma |
Date of first enrolment | 01/09/2016 |
Date of final enrolment | 31/08/2017 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
North Bristol NHS Trust
Bristol
BS10 5NB
United Kingdom
Sponsor information
Hospital/treatment centre
Research & Innovation
Learning & Research Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB
England
United Kingdom
https://ror.org/036x6gt55 |
Funders
Funder type
Government
Government organisation / National government
- Alternative name(s)
- National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
- Location
- United Kingdom
Results and Publications
Intention to publish date | 31/07/2018 |
---|---|
Individual participant data (IPD) Intention to share | Yes |
IPD sharing plan summary | Available on request |
Publication and dissemination plan | Results will be presented at an international mesothelioma research meeting such as International Mesothelioma interest Group (iMiG) and published in a peer reviewed scientific journal. |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Protocol article | protocol | 29/08/2018 | Yes | No | |
Basic results | 22/07/2019 | 22/07/2019 | No | No | |
Basic results | 21/04/2020 | No | No | ||
HRA research summary | 28/06/2023 | No | No |
Additional files
- ISRCTN45536692_BasicResults_22Jul2019.pdf
- uploaded 22/07/2019
Editorial Notes
21/04/2020: The following changes were made to the trial record:
1. Added clinicaltrialsregister.eu link to basic results (scientific).
2. The total final enrollment was added.
22/07/2019: The basic results of this trial have been uploaded as an additional file.
03/07/2019: Internal review.
20/05/2019: The overall end date was changed from 31/05/2018 to 24/07/2018.
31/08/2018: Publication reference added.
06/06/2017: Cancer Help UK lay summary link added to plain English summary field